Search - tctmd.com

Displaying 341 - 360 of 590

Sort: Relevancy | Date

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Opinion Fellow Talk

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Yashasvi Chugh, MD

August 05, 2019

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Daily News

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Michael O'Riordan

July 17, 2019

News Industry News

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

July 16, 2019

News Daily News

Elevated BP Linked to Risk of Valvular Heart Disease, Including Aortic Stenosis

Michael O'Riordan

July 12, 2019

News Daily News

Preemptive Alcohol Septal Ablation May Help Prevent LVOT Obstruction in TMVR

Yael L. Maxwell

July 11, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Industry News

BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III

July 08, 2019

News Daily News

Fragmented TAVR Care Common, Linked to Death and Readmission

L.A. McKeown

July 08, 2019

News Industry News

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

July 01, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

What’s The Future For Treating Mitral Valve Disease: Repair, Replace, or Combination Approaches?

Michael O'Riordan

June 14, 2019

News Conference News TVT 2019

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Shelley Wood

June 14, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

News Conference News SCAI 2019

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Yael L. Maxwell

June 05, 2019

Advertisement

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Pursuing Training in Structural Heart Interventions: Q&A With Mario Gössl, MD

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Elevated BP Linked to Risk of Valvular Heart Disease, Including Aortic Stenosis

Preemptive Alcohol Septal Ablation May Help Prevent LVOT Obstruction in TMVR

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III

Fragmented TAVR Care Common, Linked to Death and Readmission

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

What’s The Future For Treating Mitral Valve Disease: Repair, Replace, or Combination Approaches?

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content